Receptor Binding Inhibitor Suppresses Carcinogenesis of Cervical Cancer by Depressing Levels of FSHR and ERβ in Mice

Anti-cancer Agents in Medicinal Chemistry
Zhuandi GongSuocheng Wei

Abstract

FSH Receptor Binding Inhibitor (FRBI) blocked the binding of FSH to FSHR. Our initial study revealed FRBI reduced the maturation rate, enhanced the apoptosis of sheep Cumulus-Oocyte Complex (COCs). Little is known about whether FRBI modulates ERβ and FSHR levels in the normal uterine and cancerous tissues. The present study aimed to evaluate the FRBI effects on the expressions of Estrogen Receptor-beta (ERβ) and FSH receptor (FSHR) in the uteri. 150 mice were assigned to FRBI+FSH (COM), FSH and control groups (CG). Mice of COM-1, COM-2 and COM-3 groups were simultaneously intramuscularly injected with 500, 750 and 1000 µg FRBI with 10 IU FSH, respectively for five days. Western blotting and qPCR were utilized to determine the expression of ERβ and FSHR. In comparison with FSH group, uterine lumen and glands of COM groups became narrow. The uterine wall and endometrial epithelium were thinned, and uterine lumen became narrow. Epithelial cells were decreased. Uterine wall thicknesses of COM-1, COM-2 and COM-3 groups were reduced by 6.49%, 14.89% and 15.69% on day 30 as compared with FSH group. Uterine perimetrium thicknesses of COM-1, COM-2 and COM-3 groups were reduced by 16.17%, 17.93% and 19.92% on day 20 in comparison with FS...Continue Reading

References

Jul 7, 2007·Physiological Reviews·Nina HeldringJan-Ake Gustafsson
Apr 23, 2013·Chemical Biology & Drug Design·Rajshri M NavalakheSmita D Mahale
Dec 18, 2013·Reproductive Biology and Endocrinology : RB&E·Rachael R SullivanTimothy G Rozell
Oct 5, 2015·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·Adriana BermudezEric Leung
May 26, 2016·The Journal of Clinical Endocrinology and Metabolism·Donata Ponikwicka-TyszkoNafis A Rahman
Nov 16, 2016·Pathology Oncology Research : POR·Sabrina ZidiWassim Y Almawi
Nov 20, 2016·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Dorota Ewa Bronowicka-KłysPaweł Piotr Jagodziński
Dec 17, 2016·Trends in Pharmacological Sciences·Margaret WarnerJan-Ake Gustafsson
Sep 25, 2017·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Suocheng WeiHaoqin Liang
Dec 21, 2017·Reproductive Medicine and Biology·Pelin YaşarMesut Muyan
Jul 6, 2018·Journal of Assisted Reproduction and Genetics·Sandro SacchiAntonio La Marca
Sep 4, 2018·Anti-cancer Agents in Medicinal Chemistry·Ping YuJihong Wang
Dec 20, 2018·Brachytherapy·Alexander J LinPerry Grigsby

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis